Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Koh · SciRah

Researcher profile · Semantic Scholar

H. Koh

Share profile

H. Koh — researcher profile on SciRah

h-index: 12
Works: 26
Citations: 2,683

Most-cited papers

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
G. Sledge, M. Toi, P. Neven, J. Sohn +14 more
2017Journal of Clinical Oncology1,479 citations Open access
Semantic Scholar
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
G. Sledge, M. Toi, P. Neven, J. Sohn +15 more
2019JAMA Oncology869 citations Open access
Semantic Scholar
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
N. Rashid, H. Koh, Hilda C. Baca, Kathy J. Lin +2 more
2016Breast Cancer54 citations Open access
Semantic Scholar
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
A. Parikh, F. Lee, L. Yau, H. Koh +7 more
2018Clinical Cancer Research48 citations Open access
Semantic Scholar
Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System
N. Rashid, H. Koh, Hilda C. Baca, Zhao-Liang Li +3 more
2015Journal of Managed Care & Specialty Pharmacy48 citations Open access
Semantic Scholar
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
S. Tomlins, D. Hovelson, J. Suga, Daniel M. Anderson +40 more
2021JCO Precision Oncology34 citations Open access
Semantic Scholar
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
H. Lenz, F. Lee, L. Yau, H. Koh +5 more
201631 citations
Semantic Scholar
MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
G. Sledge, M. Toi, P. Neven, J. Sohn +15 more
2019Annals of Oncology22 citations Open access
Semantic Scholar
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.
S. Gettinger, Sen Zhang, J. Hodgson, L. Bazhenova +15 more
201617 citations
Semantic Scholar
MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy
G. Sledge, M. Toi, P. Neven, J. Sohn +14 more
201716 citations
Semantic Scholar
Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A. Llombart-Cussac, G. Sledge, M. Toi, P. Neven +13 more
2023Cancer Research12 citations
Semantic Scholar
Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
L. Bazhenova, J. Hodgson, Corey J. Langer, G. Simon +15 more
201712 citations
Semantic Scholar
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
P. Neven, S. Johnston, M. Toi, J. Sohn +14 more
2021Clinical Cancer Research10 citations Open access
Semantic Scholar
Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system
N. Rashid, H. Koh, Kathy J. Lin, B. Stwalley +1 more
2018Journal of Oncology Pharmacy Practice9 citations
Semantic Scholar
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
H. Lenz, F. Lee, L. Yau, H. Koh +5 more
20168 citations
Semantic Scholar
Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2
P. Neven, M. Toi, J. Sohn, Kenichi Inoue +12 more
2025JCO Oncology Advances5 citations Open access
Semantic Scholar
IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.
R. Jotte, M. Batus, E. Bernicker, M. Copur +9 more
20204 citations
Semantic Scholar
Final Overall Survival Analysis of MONARCH 2: A Phase 3 Trial of Abemaciclib plus Fulvestrant in Patients with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
E. Grischke, A. Llombart-Cussac, M. Toi, P. Neven +13 more
2023Senologie - Zeitschrift für Mammadiagnostik und -therapie2 citations
Semantic Scholar
MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.
P. Neven, S. Johnston, M. Toi, Joohyuk Sohn +14 more
2020Journal of Clinical Oncology2 citations
Semantic Scholar
Real World Treatment Patterns in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors in First Line in an Integrated Healthcare System
N. Rashid, H. Koh, Kathy J. Lin, C. Dimaano +1 more
20152 citations Open access
Semantic Scholar
PCR-based comprehensive genomic profiling (PCR-CGP): Feasibility from >20,000 tumor tissue specimens (TTS) and predicted impact on actionable biomarker identification versus hybrid capture (H)-CGP and plasma (P)-CGP.
D. Rhodes, D. Hovelson, J. Suga, Daniel M. Anderson +16 more
20201 citations
Semantic Scholar
253PAbemaciclib plus fulvestrant in patients (pts) with HR+/HER2- endocrine therapy naïve (EN) advanced breast cancer - an exploratory analysis of MONARCH 2
P. Kaufman, H. Iwata, P. Nikolinakos, J. Beck +8 more
20171 citations Open access
Semantic Scholar
Patterns and Predictors of First-Line Therapy Use Among Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant in an Integrated Healthcare System
N. Rashid, Yun Su, G. Aranda, Yi-Lin Wu +1 more
20141 citations
Semantic Scholar
Abstract P3-08-01: MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors
P. Neven, S. Johnston, M. Toi, J. Sohn +14 more
2020Poster Session Abstracts0 citations
Semantic Scholar
Comprehensive genomic profiling of 30,000 consecutive solid tumors
S. Tomlins, D. Hovelson, J. Suga, Daniel M. Anderson +40 more
2020medRxiv0 citations Open access
Semantic Scholar
Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer (mCRC).
A. Starodub, Sachdev Thomas, F. Lee, Vallathucherry C. Harish +10 more
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Llombart-Cussac×10
Invite
A. Llombart-Cussac — researcher profile on SciRah
N. Masuda×9
Invite
N. Masuda — researcher profile on SciRah
P. Neven×8
Invite
P. Neven — researcher profile on SciRah
X. Pivot×8
Invite
X. Pivot — researcher profile on SciRah

×8

Invite

M. Okera — researcher profile on SciRah

Invite

G. Sledge — researcher profile on SciRah

Invite

M. Toi — researcher profile on SciRah

Invite

J. Sohn — researcher profile on SciRah

Invite

K. Inoue — researcher profile on SciRah

Invite

O. Burdaeva — researcher profile on SciRah

Invite

P. Kaufman — researcher profile on SciRah

Invite

E. Grischke — researcher profile on SciRah